




Rec'd PCT/PTO 20 JUL 2005  
CT/GB 2004 / 000200



INVESTOR IN PEOPLE

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)



The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



*L. Mahoney*

Signed

Dated 10 February 2004

**BEST AVAILABLE COPY**

Patents Form 1/77

Patents Act 1977  
(Rule 16)

THE PATENT OFFICE

20 JAN 2003

RECEIVED BY FAX

The  
Patent  
Office20JAN03 E778388-1 002973  
P01/7700 0.00-0301225.9

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP9 1RH**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

SPG/P101751GB

2. Patent application number

(The Patent Office will fill in this part)

0301225.9

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)University of Sunderland  
Langham Tower  
Ryhope Road  
Sunderland  
SR2 7EEPatents ADP number (*if you know it*)

If the applicant is a corporate body, give the country/state of its incorporation

6401442001

4. Title of the invention

Surface Layer Immuno-Chromatography

5. Name of your agent (*if you have one*)

Harrison Goddard Foote

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)31 St Saviourgate  
YORK  
YO1 8NQPatents ADP number (*if you know it*)

07914237002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number  
(*if you know it*)Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer 'Yes' if*

- a) any applicant named in part 3 is not an inventor, or Yes  
 b) there is an inventor who is not named as an applicant, or  
 c) any named applicant is a corporate body.  
 See note (d))

Patents Form 1/77

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

## Continuation sheets of this form

Description 5

Claim(s) 3

Abstract -

Drawing(s) -

10. If you are also filing any of the following, state how many against each item.

## Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 8/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

S. P. Gilholm

20/01/03

12. Name and daytime telephone number of person to contact in the United Kingdom

S P Gilholm

01904 732120

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 600505.  
 b) Write your answers in capital letters using black ink or you may type them.  
 c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.  
 d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.  
 e) Once you have filled in the form you must remember to sign and date it.  
 f) For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

### Surface Layer Affinity-Chromatography

Immuno-chromatography is currently performed in two major formats. The first is performed within gels when development is achieved by passive diffusion or is  
5 electrochemically induced, and the second is performed in flow. In the former using gels, radial immunodiffusion is the most commonly used system with a preformed gel often located within a circular plate in which a central well is present in the gel together with additional wells located around the edge of the gel. Antiserum or antigen is placed in the central well and antigen or antiserum is placed in the  
10 peripheral wells. Passive diffusion occurs within the gel and white bands of immunocomplex are seen within the gel due to antibody-antigen complex formation. In the electrochemical system antibody/antigen migration within the gel is induced using an electric current.

15 In the flow-based systems the antibody or antigen is often immobilised within a cartridge which is paced with a liquid flow system such as a flow injection analysis system. The complementary antigen or antibody is injected and flows through the cartridge where specific interactions take place. Often the component that is injected carries a label that can be detected downstream, thereby producing a signal.  
20 Alternatively flow occurs over a planar surface as in lateral flow diffusion immunoassay systems where flow is induced by membrane wetting/capillarity.

In the new format the equivalent immunoreactions take place in flow between an immobilised component and one in solution as above but this now occurs on the  
25 surface of a dip strip residing within a buffer solution. In this case flow across the surface of the strip occurs due to the higher density of a solution containing one of the immunoreagents that is initially present at the top of the strip that is itself standing in the buffer solution. Since the strip is nearly upright this denser solution slowly rolls down the surface of the strip presenting the reagent in the flowing phase  
30 to the immobilised reagent on the surface of the dip strip.

Thus according to the invention we provide an affinity-chromatography assay system comprising with an immobilised component containing a bio-reagent and a flowable component containing a complimentary bio-reagent characterised in that the immobilised component is supported on a dip<sup>1</sup> strip or other planar surface and the  
5 flowable component of high density is adapted to flow down the dip strip.

In order for this phenomenon to work certain criteria must be met. Firstly the denser solution must be retained in a discrete volume as it passes as a layer over the surface rather than rapidly diffusing into the bulk of the buffer solution. Secondly the dip  
10 strip must possess certain properties that result in attraction of the rolling surface layer again leading to retention of the integrity of this mobile phase. To achieve the first criterion we have carefully chosen the constituents of the rolling phase to include a polymeric agent such as a protein and/or a polysaccharide, a detergent and a buffer of optimal pH, and for the second we use a membrane that is both hydrophobic and  
15 wettable.

The system can be used as an immuno-chromatography system and assays performed in either competitive or non-competitive immunoassay formats. In the former the immobilised spot is either antibody or antigen. For immobilised antibody, a labelled  
20 antigen is deposited in a band above the spot in a cellulose square. A drop of sample containing the antigen is added to this square and after a suitable interval (1-10 min) the whole strip is immersed in a buffer solution. The dense mixture of labelled and unlabelled antigen flows over the spot of antibody and competition for binding takes place. If the antigen is immobilised at the spot, a labelled antibody replaces the  
25 labelled antigen in the cellulose square and the assay proceeds as before.

The system can also be performed in a non-competitive immunoassay format when a spot of capture antibody is immobilised on the strip. Labelled antibody is deposited on the cellulose square above the first spot. The strip is placed in the sample solution  
30 containing the antigen so that the upper square is immersed. Incubation now takes place during which antigen in the solution is captured by immobilised antibody on

the spot. At the same time the labelled antibody is reconstituted in a dense solution that flows over the spot after about 5-10 minutes following insertion of the strip into the sample solution. This time lag enables antigen molecules to be captured on the spot prior to arrival of the surface layer containing the labelled antibody. This second  
5 antibody labels the captured antigen on the spot's surface.

In addition any label can be used. If a fluorescent or coloured label is used with the antibody or antigen, then a fluorescent or coloured spot will result following the first incubation, making the assay a single step system.

10

If an enzyme label is used then a modified sequence of steps can be used in the non-competitive assay. In this, enzyme-labelled antibody is now added to the cellulose square attached to the bottom of the strip beneath the spot of immobilised capture antibody. A second cellulose square is also attached as before above this spot but this  
15 contains a dried solution of substrate for the enzyme plus a biopolymer such as dextran. The strip is placed in a limited volume of sample as before so as not to wet the upper cellulose square. The dense reconstituted solution of labelled antibody flows to the bottom of the container and stays there as a separate layer. At the same time antigen in solution is captured by the antibody on the spot. At the end of this  
20 incubation step (5-10 minutes) the solution is stirred using the dip strip. This causes the labelled antibody to be homogeneously distributed within the solution and the antibody can now bind to the captured antigen on the spot. Finally the volume in the container is increased to wet the upper cellulose square. The substrate is now reconstituted as a dense solution that flows over the spot when substrate to product  
25 conversion takes place resulting in a coloured spot.

According to a further aspect of the invention we provide a method of conducting immuno-chromatography assays which comprise the use of an assay system as hereinbefore described.

30

This new surface layer chromatography phenomenon could, in theory, also be used as a generic chromatographic method for separation of analyte mixtures if the components have different binding affinities for the surface. For example, it is well known that biological polymers such as proteins and DNA/RNA bind to cellulose nitrate as this is used in DNA- and protein-blotting following electrophoresis. We have also observed that for antibodies the rate of binding to this surface is pH sensitive [1]. Hence it should be possible to introduce a mixture of biological polymers onto a cellulose strip above a cellulose nitrate square. The pH and density of the buffer used would be such that surface layer chromatography will ensue when the strip is immersed into a second buffer solution chosen to optimise the binding of the biopolymers to the surface. Under these conditions, different binding interactions will take place between the bio-molecules and the surface as the mobile phase layer rolls over the surface. This should lead to separation of the components during this development phase. The strip would then be removed and the membrane treated to visualise, using established methods, the now immobilised components of the mixture.

The invention will now be illustrated with reference to the accompanying example.

20

#### Example 1

In an example of this new immunochromatographic system that we term Surface Layer Immuno-Chromatography (SLIC), a small square of cellulose nitrate membrane is pre-treated via established methods with a specific antibody to an antigen such as savinase, to produce a spot of immobilised reagent. This square is stuck on the surface of a plastic strip pre-coated with one sticky surface. Above this is stuck a second strip of cellulose impregnated with a dried solution of the same antibody labelled with the reporter enzyme alkaline phosphatase, together with bovine serum albumin (BSA) and Tween 20. The solution used for this deposition is Tris (pH 9.3) and a volume of 10  $\mu$ l is used. The composition of this solution is 0.1 % w/v BSA, 0.1% w/v Tween 20, enzyme-labelled antibody diluted 1:1000 in Tris

buffer (0.1M). The reagents in this format when stored at room temperature in a desiccator are stable on the strip for at least 14 days.

To perform the assay, a solution of savinase (0.3 ml) in Tris buffer is placed in a test tube such as a conventional 96 well microtitre plate. The dip strip is now inserted into the well when both squares are covered by the sample. On wetting, the reagents within the square of cellulose pass into solution. Due to its higher density this solution now flows as a layer down the surface of the strip and eventually passes over the lower square containing the spot of immobilised antibody. In the time interval between immersion of the strip and arrival of the flowing phase, savinase molecules in the bulk solution will have been captured by the immobilised antibodies on the lower spot. On arrival of the flowing phase, labelled antibody will bind to the captured antigen molecules as in a conventional sandwich-type ELISA, as the solution flows over the spot. This first incubation period is typically 15 minutes.

15

The strip is removed from the well and placed in wells containing the commonly used substrate mixture for alkaline phosphatase, bromochloroindolyl phosphate (BCIP) and nitroblue tetrazolium salt (NBT). A purple/blue colour develops after 1 minute's incubation, the intensity of which is directly proportional to the amount of savinase captured on the spot during the first incubation step, and hence the concentration of savinase in the sample. The top square is also coloured purple/blue. A scan of the resulting strips is shown for this analyte. It should be noted that we use 12 such strips in a comb-like format as this enables analysis of up to 96 samples/standards (8x12) to be performed with a single microtitre plate. It will be noted that visual discrimination between the zero and the 5 ng/ml standard is clearly seen.

30 P101751GB.2



**Claims**

1. An affinity-chromatography assay system comprising with an immobilised component containing a bio-reagent and a flowable component containing a  
5 complimentary bio-reagent characterised in that the immobilised component is supported on a dip strip or planar surface and the flowable component is adapted to flow down the dip strip of high density.
2. A affinity-chromatography assay system according to claim 1 characterised in  
10 that the flowable component is of a higher density than the bulk solution.
3. An affinity-chromatography assay system according to claim 1 characterised in that immunoreagent is an antigen or antibody.
- 15 4. An affinity-chromatography assay system according to claim 1 characterised in that the flowable component is retained in a discrete volume.
5. An affinity-chromatography assay system according to claim 1 characterised in that the constituents of the flowable phase include a bio-polymer, a detergent and a  
20 buffer of optimal pH
6. An affinity-chromatography assay system according to claim 1 characterised in that the immobilised component possesses properties that result in attraction of the flowable component.  
25
7. An affinity-chromatography assay system according to claim 6 characterised in that the attraction of the flowable component is achieved by a membrane.
8. An affinity-chromatography assay system according to claim 7 characterised  
30 in that the membrane is both hydrophobic and wettable.

9. An affinity-chromatography assay system according to claim 3 characterised in that the assay is either a competitive or non-competitive immunoassay using appropriate combinations of labelled antigen or labelled antibody with their complementary unlabelled counterparts.

5

10. An affinity-chromatography assay system according to claim 9 characterised in that the label is a fluorescent or coloured label.

11. A method of conducting an affinity-chromatography assay which comprises  
10 the use of an assay system according to claim 1.

12. A method according to claim 11 characterised in that the dipstrip that is stood substantially upright in a buffer solution.

13. A method according to claim 11 characterised in that the flowable component  
15 is dispensed adjacent the upper or lower part of the dipstrip.

14. A method according to claim 11 characterised in that the method comprises the separation of analyte mixtures.

20

15. A method according to claim 11 characterised in that the components have different binding affinities for the surface.

16. A method according to claim 11 characterised in that the method comprises a  
25 single step assay.

17. A method according to claim 11 characterised in that the method comprises the separation of biological polymers.

18. A method according to claim 17 characterised in that the biological polymers  
30 are selected from proteins and DNA/RNA.

19. An affinity-chromatography assay system or a method substantially as described with reference to the accompanying examples.

5

10

15

20

25

30

35

40

45 P101751GB.1

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**